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Abstract  
Introduction: [1-11C]acetate positron emission tomography (PET) is used for myocardial 
studies. In the myocardium, mitochondrial acetyl-CoA synthetase (ACSS1) mainly 
contributes to the radiopharmaceutical uptake. [1-11C]acetate PET is also used for tumor 
diagnosis; however, the uptake mechanism of radiolabeled acetate in tumors remains unclear. 
Our previous study reported that cytosolic acetyl-CoA synthetase (ACSS2) was expressed in 
tumor cells and up-regulated under hypoxia; whereas, expression of ACSS1 was negligible 
regardless of the oxygen conditions. We also indicated that ACSS2 is a bi-directional enzyme 
that controls acetyl-CoA / acetate metabolism in tumor cells. In this study, to elucidate the 
basic mechanism of tumor acetate uptake, we focused on ACSS2 and investigated the role of 
ACSS2 in the uptake of radiolabeled acetate in tumor cells. 
Methods: [1-14C]acetate uptake and ACSS2 expression were examined in four tumor cell 
lines under normoxia or hypoxia. An ACSS2 knockdown study was also performed. 
Results: [1-14C]acetate uptake was increased in the tumor cells under hypoxia. This pattern 
followed that of ACSS2 expression. The incorporated 14C was mostly distributed in the 
lipid-soluble fractions, and this tendency increased under hypoxia. ACSS2 knock down led to 
a corresponding reduction in [1-14C]acetate uptake in all tumor cell lines examined under 
normoxia and hypoxia. 
Conclusions: ACSS2 plays an important role in the uptake of radiolabeled acetate in tumor 
cells, which is different from that in the myocardium, which mainly involves ACSS1. The 
uptake of radiolabeled acetate in tumors increased under hypoxia along with up-regulation of 
ACSS2 expression. This suggests a possible mechanism for acetate PET for tumors.
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1. Introduction 
[1-11C]acetate positron emission tomography (PET) is used for the evaluation of 
myocardial blood flow and oxidative metabolism [1-4]. In the myocardium, the uptake 
mechanism of radiolabeled acetate is well-understood, i.e., the acetyl-CoA synthetase (ACSS, 
EC 6.2.1.1; ATP + acetate + CoA ↔ AMP + diphosphate + acetyl-CoA) distributed in 
mitochondria (termed ACSS1 in this study) is highly expressed compared with that 
distributed in the cytosol (termed ACSS2) and contributes to uptake of radiolabeled acetate 
[5-7]. It was also demonstrated that the radiolabeled acetate incorporated by the heart is 
mainly used for oxidation and metabolized into CO2 via the TCA cycle, but is also partly 
used for lipid synthesis [5, 8-11]. 
[1-11C]acetate PET has also become a useful tool for detecting various kinds of 
malignant tumors, e.g., prostate cancer [12, 13], renal carcinoma [14], hepatocellular 
carcinoma [15], brain astrocytoma [16], and glioma [17]. Alternatively, [18F]fluoroacetate is 
being developed as an analog of [1-11C]acetate [18, 19] and has been shown to be useful for 
detecting prostate cancer by PET studies [20, 21]. However, information on the exact uptake 
mechanism of radiolabeled acetate in tumor cells is limited. 
So far, several studies on the uptake of radiolabeled acetate in tumor cells have been 
conducted. Yoshimoto et al. examined [1-14C]acetate uptake and metabolic fate under 
normoxia in four tumor cell lines including colon adenocarcinoma, nasal septum 
quasi-diploid tumor, ovary carcinoma, and melanoma as well as in a non-tumor fibroblast cell 
line to elucidate the implication of [1-11C]acetate-PET imaging [22], and revealed that the 
tumor cells showed higher [1-14C]acetate uptake than fibroblast cells under normoxia and that 
the tumor cells incorporated [1-14C]acetate into lipids rather than CO2 via the TCA cycle and 
amino acids. In addition, Hara et al. reported that [1-14C]acetate uptake is accelerated under 
hypoxia in prostate cancer cells [23]. 
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Concerning the gene expression of tumor ACSS, our previous study revealed that 
tumor cell lines, including Lewis lung carcinoma, LLC (LL/2); melanoma, B16; colon 
carcinoma, Colon (Colon-26); and mammary carcinoma, C127I, expressed little ACSS1, but 
greater cytosolic ACSS2 and that the expression of ACSS2 was up-regulated under hypoxia. 
We also found that ACSS2 plays an important role in hypoxic survival in tumor cells [24]. 
Interestingly, our data also demonstrated that ACSS2 participates in the reversible reaction 
between acetyl-CoA and acetate in tumor cells; i.e., ACSS2 is a bi-directional enzyme 
mediating a buffering role in tumor acetyl-CoA / acetate metabolism. These facts prompted 
us to hypothesize that ACSS2 might mediate uptake of radiolabeled acetate in tumor cells and 
that the uptake rate of radiolabeled acetate in tumor cells would be increased under hypoxia 
along with up-regulation of ACSS2 expression. In this study, to understand the uptake 
mechanism of radiolabeled acetate in tumor cells as a basis of tumor acetate PET, we 
characterized the patterns of [1-14C]acetate uptake and ACSS2 expression in tumor cells and 
considered the role of tumor ACSS2 in the uptake of radiolabeled acetate. 
 
2. Materials and methods 
2.1. Cells and cultivation 
Four mouse tumor cell lines were used in this study, LLC (LL/2) (CRL-1642, 
American Type Culture Collection or ATCC, mouse Lewis lung carcinoma), B16 (RCB1283, 
Riken Cell Bank, mouse melanoma), Colon (Colon-26; TKG 0518, Cell Resource Centre for 
Biomedical Research, Tohoku University, mouse colon carcinoma), and C127I (CRL-1616, 
ATCC, mouse mammary carcinoma). As a reference, a mouse fibroblast cell line, BALB/3T3 
clone A31 (3T3; CCL-163, ATCC), was used. For the ACSS2 knock down study, tumor cells 
in which ACSS2 expression was inhibited by RNA interference (RNAi) were used. These 
RNAi tumor cells were previously constructed using lentiviral particles (Mission lentiviral 
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transduction particles; SHVRS-NM 019811; Sigma, Poole, UK) carrying expression cassettes 
encoding ACSS2-targeting single-hairpin RNA (shRNA). Non-targeting shRNA (SHC002V, 
Sigma) was also used as a negative control [24-26]. The cells were incubated in a humidified 
atmosphere of 5% CO2 in air (normoxia) at 37 °C. Dulbecco’s modified Eagle’s medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and antibiotics 
was used for growth. Exponentially growing cells were used for the experiments. Hypoxia 
(1.2% O2, 93.8% N2 and 5% CO2) was achieved with a Personal Multi Gas Incubator (Astec, 
Fukuoka, Japan). The cells were trypsinized to detach them from the plates, and the number 
of viable cells was counted by the trypan blue dye-exclusion method. 
 
2.2. [1-14C]acetate uptake study 
In this experiment, we optimized the number of cells for seeding to roughly control 
the number of cells present during the uptake study (LLC, B16, and Colon: 5 × 104, C127I: 8 
× 104, 3T3: 1 × 105) in 1 ml growth medium per well in 24-well plates. The cells were 
incubated under normoxia for 24 h, and the cells for the hypoxic study were additionally 
pretreated with 2 h or 6 h hypoxia. After the preincubation, 500 μl growth medium containing 
37 kBq of [1-14C]acetate (2.07 GBq/mmol) (GE Healthcare, Pollards, UK) were added to 
each well, and the cells were incubated for 1 h under normoxia or hypoxia. We adopted a 
similar concentration of [1-14C]acetate to that in Yoshimoto et al. [22]. Then, the medium was 
removed, and the cells were washed twice with ice-cold PBS. The resultant cells were lysed 
with 500 μl of 0.2N NaOH for 2 h at room temperature or processed by the Bligh and Dyer 
extraction method to separate the lipid- and water-soluble fractions [27]. The radioactivity of 
mixture of the lysate or separated fractions and a liquid scintillator (ACSII, GE Healthcare) 
was measured using a liquid scintillation counter (LSC-5000, Aloka, Tokyo, Japan). The 
number of cells treated before cell lysis was counted. In addition, the pretreatment with 
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long-term hypoxia (24 h) was also tested in the same manner. 
 
2.3. Gene expression analysis.  
Total RNA isolation was performed with a Micro-to-Midi total RNA purification 
system (Invitrogen). cDNA was synthesized from 1 μg of total RNA using the ReverTra Ace 
qPCR RT Kit (Toyobo, Osaka, Japan) and was subjected to real-time PCR. The real-time 
PCR was performed with Realtime PCR Master Mix (Toyobo) and TaqMan gene expression 
assays (Applied Biosystems, Foster City, CA, USA) using an ABI PRISM 7000 sequence 
detection system (Applied Biosystems) in total reaction volumes of 20 μl containing 10 μl 
Realtime PCR Master Mix, 9 μl 1/10 cDNA template, and 1 μl 20× TaqMan gene-expression 
assay (ACSS2, Mm00480101; β-actin, Mm00607939). PCR was carried out for 1 min at 
95 °C, followed by 40 cycles at 95°C for 15 s and at 60°C for 1 min. ACSS2 mRNA was 
quantified by the comparative CT method using β-actin expression as the endogenous control 
[28]. 
 
2.4. Statistical analysis. 
Data are expressed as means and standard deviations. P values were calculated by 
the two-sided t-test for comparison between two groups. ANOVA was used for comparison 
between multiple treatment groups. P values < 0.05 were considered statistically significant. 
Values from four independent experiments are presented. 
 
3. Results  <Please locate Fig. 1 and Table 1 around here.> 
3.1 [1-14C]acetate uptake study 
Fig. 1A shows [1-14C]acetate uptake for 1 h in the cells examined. Under normoxic 
Yoshii et al.  
Mechanism of tumor acetate uptake 
 
7 
 
conditions, all tumor cells showed higher [1-14C]acetate uptake than the 3T3 fibroblast cells: 
1.3-fold in LLC and B16, 1.6-fold in Colon, and 1.2-fold in C127I (P < 0.001 in Colon; P < 
0.01 in LLC and C127I; P < 0.02 in B16). We also tested the [1-14C]acetate uptake for 1 h 
under hypoxic conditions. In this study, the cells were treated with 2 h or 6 h hypoxia prior to 
the uptake study. In four all tumor cell lines, the [1-14C]acetate uptake was much increased 
under hypoxia compared with normoxia; however, the 3T3 fibroblast cells did not show any 
increase in [1-14C]acetate uptake under hypoxia. In the cells treated with 2 h hypoxia 
beforehand, the values were 1.3-fold, 1.2-fold, 1.6-fold, and 1.2-fold larger in LLC, B16, 
Colon, and C127I, respectively, compared with each cell type under normoxia (P < 0.01 in 
Colon and C127I; P < 0.02 in LLC and B16). Similarly, the cells treated with 6 h hypoxia 
beforehand showed increased [1-14C]acetate uptake, compared with normoxia: 1.4-fold, 
1.2-fold, 1.5-fold, and 1.4-fold larger than each cell type under normoxia in LLC, B16, Colon, 
and C127I, respectively (P < 0.01 in LLC, Colon, and C127I; P < 0.04 in B16). There was no 
significant difference between 2 h and 6 h hypoxic pre-treatments. 
 
3.2 ACSS2 expression analysis 
Fig. 1B shows the expression pattern of transcripts encoding cytosolic ACSS2 in the 
cells examined. The pattern of tumor ACSS2 expression resembled that of [1-14C]acetate 
uptake. Namely, tumor ACSS2 expression showed an increase compared with that of the 3T3 
fibroblast cells: 1.5-fold in LLC, 1.9-fold B16, 2.4-fold in Colon, and 2.2-fold in C127I, 
respectively (P < 0.001). Also, the expression of ACSS2 mRNA increased under hypoxia in 
tumor cells; whereas, it decreased in the 3T3 fibroblast cells. The values of ACSS2 
expression were 1.4-fold and 1.6-fold larger in LLC, 1.5-fold and 1.1-fold larger in B16, 
1.6-fold and 1.7-fold larger in Colon, and 1.1-fold and 1.6-fold larger in C127I, after 2h and 
6h hypoxic treatment, respectively, compared with each cell type under normoxia (P < 0.01 
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in LLC, B16 and Colon; P < 0.03 in C127I).  
 
3.3 Effect of long-term hypoxia to [1-14C]acetate uptake and ACSS2 expression <Please 
locate Table 1 around here.> 
Table 1 shows the ratios of the long-term hypoxic pretreatment (24 h) and short-term 
hypoxic pretreatment (2 h or 6 h) to normoxic treatment in the [1-14C]acetate uptake and 
ACSS2 gene expression. In all tumor cell lines, cells pretreated with 24 h hypoxia showed 
significant increase of [1-14C]acetate uptake and ACSS2 expression, compared with normoxia. 
This tendency was similar to that seen in the cells pretreated with 2 h or 6 h hypoxia. 
 
3.4 Distribution ratio of radioactivity in fractions separated from tumor cells <Please locate 
Fig. 2 around here.> 
The fate of the 14C incorporated into tumor cells under normoxia or hypoxia was 
further examined. The 14C incorporated into the tumor cells was mostly distributed in the 
lipid-soluble fraction: 81.6 % and 87.6 % in LLC, 70.2 % and 79.3 % in B16, 85.8 % and 
91.4 % in Colon, and 74.1 % and 86.0 % in C127I of the total 14C incorporated into the cells, 
under normoxia and hypoxia, respectively (Fig. 2). The proportion incorporated into the 
lipid-soluble fraction under hypoxia tended to be higher than that under normoxia, and the 
increase was significant in the LLC, Colon, and C127I cells (P < 0.05 in LLC; P < 0.001 in 
Colon and C127I); whereas, it was marginal and not significant in the B16 cells. 
 
3.5 Involvement of ACSS2 in tumor [1-14C]acetate uptake <Please locate Fig. 3 here.> 
To test the involvement of ACSS2 in acetate tracer uptake in tumor cells, we 
examined [1-14C]acetate uptake in RNAi cells derived from the four tumor cell lines. In the 
ACSS2-RNAi tumor cells, the expression of ACSS2 was decreased compared with 
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control-RNAi tumor cells in all the tumor cell lines examined (Fig. 3A-D, upper). 
Furthermore, in the ACSS2-RNAi tumor cells, knock down of ACSS2 caused a 
corresponding reduction in [1-14C]acetate uptake in all examined tumor cell lines under 
normoxia (Fig. 3A-D, lower). Under hypoxic conditions, a similar tendency was also 
confirmed in all examined tumor cell lines (data not shown). 
 
4. Discussion 
We characterized [1-14C]acetate uptake in tumor cells, including LLC, B16, Colon, 
and C127I cells. All the tumor cells we examined incorporated larger amounts of 
[1-14C]acetate than the 3T3 fibroblast cells under normoxia. Our results showed concordance 
with a previous report by Yoshimoto et al that used other tumor cell lines. [22]. We also 
confirmed the acceleration of [1-14C]acetate uptake under hypoxia in all tumor cell lines 
examined. Hara et al. reported an increase in [1-14C]acetate uptake under hypoxia in prostate 
cancer cells [23]. Our results revealed a similar tendency. 
In the present study, we found that the pattern of [1-14C]acetate uptake resembled the 
pattern of cytosolic ACSS2 mRNA expression in the four tumor cell lines examined (Fig. 1 
and Table 1). In addition, from the RNAi studies, we revealed that knockdown of ACSS2 in 
the tumor cells led to a corresponding reduction in [1-14C]acetate uptake under normoxia and 
hypoxia, respectively. Taken together, it can be concluded that ACSS2 was involved in 
[1-14C]acetate uptake in the tumor cells and that up-regulation of ACSS2 expression under 
hypoxia led to an increase in [1-14C]acetate uptake.  
Hara et al. demonstrated that prostate cancer cells pretreated with 4 h or 5 h hypoxia 
showed acceleration of [1-14C]acetate uptake under hypoxia [23]. In this study, we used cells 
that were pretreated with 2 h or 6 h hypoxia for the uptake experiments to evaluate 
[1-14C]acetate uptake under hypoxia. We found that in both hypoxic treatment groups of each 
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tumor cell, [1-14C]acetate uptake and ACSS2 expression were increased under hypoxia, 
compared with normoxia. This indicates that the rate of [1-14C]acetate uptake under hypoxia 
became faster than that under normoxia, which mirrors the activation of ACSS2 expression. 
Therefore, hypoxia induced the tumor cells to up-regulate ACSS2 expression and 
[1-14C]acetate uptake within 2 h. Similarly, the long-term hypoxic treatment led to increase 
[1-14C]acetate uptake and ACSS2 expression. This means that, in tumor cells under more 
chronic hypoxic conditions, the acceleration of [1-14C]acetate uptake could be also caused by 
the up-regulation of ACSS2 expression. 
We have previously reported that the tumor cells used in this study expressed 
cytosolic ACSS2 and that the expression of ACSS2 was increased under hypoxia; whereas, 
mitochondrial ACSS1 was little expressed regardless of the oxygen conditions [24]. In this 
study, we showed that tumor [1-14C]acetate uptake reflected the expression of cytosolic 
ACSS2 and that the cytosolic ACSS2 was involved in [1-14C]acetate uptake in these tumor 
cell lines. This indicates that the uptake of radiolabeled acetate reflects cytosolic ACSS2 
activity rather than mitochondrial ACSS1 in these tumor cell lines. In contrast, it has been 
reported that in the myocardium mitochondrial ACSS1 is more highly expressed than ACSS2 
and is involved in uptake of radiolabeled acetate [5]. This means that the uptake mechanism 
of radiolabeled acetate in tumor cells might be different from that in the myocardium. 
Furthermore, the metabolic fate of the incorporated acetate seems different between tumor 
cells and the myocardium; namely, tumor cells mainly metabolize radiolabeled acetate into 
lipids [22]; whereas, the myocardium mainly metabolizes it into CO2 [5, 8-11]. 
ACSS2 is known to be highly expressed in the liver as a lipogenic enzyme that 
incorporates acetate into lipids [5, 29, 30]. On the other hand, our studies have demonstrated 
that ACSS2 can mediate the reversible reaction between acetyl-CoA and acetate in tumor 
cells ([24], this study). In this study, we administered 37 kBq of [1-14C]acetate (2.07 
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GBq/mmol) to tumor cells, which can be estimated as a 3 – 9-fold larger amount of acetate 
compared with the level of tumor acetate excretion reported previously [24]. This suggests 
that the reactions of tumor ACSS2 are affected by the concentrations of acetate and 
acetyl-CoA. 
Löffler and Schneider reported that, under hypoxia, the proportion of [U-14C]acetate 
incorporated into lipids is increased in Ehrlich ascites tumor cells [31]. Similarly, this study 
showed that [1-14C]acetate incorporation into the lipid-soluble fraction tended to be enhanced 
in tumor cells under hypoxia. On the other hand, Vāvere et al. showed that [1-11C]acetate 
uptake is correlated with expression of fatty acid synthetase (FAS) by in vitro and in vivo 
study [32] and a recent study by Furuta et al. demonstrated that hypoxia up-regulates FAS via 
phosphorylation of Akt followed by activation of hypoxia-inducible factor 1 (HIF-1) in 
various types of tumor cells [33]. According to Furuta et al. [33], the expression of FAS is 
activated by H2O2 generation under hypoxia, and the up-regulation of FAS leads to 
hypoxia-induced chemoresistance in tumor cells, which suggests that fatty acid synthesis is 
activated under hypoxia to adapt to environments involving hypoxic stress in tumor cells. 
Taking these studies and our results together, it is reasonable to assume that the incorporated 
acetate in tumor cells under hypoxia is used for activated fatty acid synthesis and is stored in 
the lipid-soluble fractions of tumor cells. In other words, radiolabeled acetate would be a 
useful marker that indicates activated FAS expression under hypoxia. 
Consequently, in this paper, we found that uptake of radiolabeled acetate reflects 
ACSS2 expression in tumor cells, which helps to elucidate the basis of tumor acetate PET. 
However, at this moment, our findings are limited to in vitro conditions. To further interpret 
tumor acetate PET, detailed information, such as on the metabolic fate of radiolabeled acetate 
in vivo and on the levels of acetate or acetyl-CoA in intact tumors, should be obtained. 
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Figure Legends 
 
Fig. 1. [1-14C]acetate uptake (A) and ACSS2 mRNA expression (B) in tumor cells (LLC, B16, 
Colon, and C127I) and fibroblast cells (3T3) under normoxia and in the same cells under 
hypoxia after pretreatment with 2 h hypoxia or 6 h hypoxia. (A) [1-14C]acetate uptake in the 
tumor cells was higher than in the 3T3 cells under normoxia (* P < 0.02, ** P < 0.01, *** P 
< 0.001). [1-14C]acetate uptake in the tumor cells increased under hypoxia (†P < 0.04, †† P < 
0.02, ††† P < 0.01), but not in 3T3. NS = not significant. (B) ACSS2 expression under 
normoxia was higher in the tumor cells compared with the 3T3 cells (P * < 0.001). The 
values were increased under hypoxia in the tumor cells, but decreased in the 3T3 cells († < 
0.03, †† < 0.01, ††† < 0.001). 
 
Fig. 2. Distribution of incorporated 14C into the lipid- and water-soluble fractions of tumor 
cells (LLC, B16, Colon, and C127I cells) after [1-14C]acetate uptake. The asterisks indicate 
the statistical significance between normoxia and hypoxia (* P < 0.05, ** P < 0.001). The 
data indicates the proportion of 14C radioactivity in the lipid-soluble fractions (gray areas) 
and water-soluble fractions (white areas).  
 
Fig. 3. ACSS2 knockdown decreased [1-14C]acetate uptake in tumor cells (LLC, B16, Colon, 
and C127I). The asterisks indicate statistical significance (* P < 0.01, ** P < 0.005, *** P < 
0.001). The data indicates the percentages of ACSS2 mRNA expression (upper) and 14C 
incorporation (lower) in ACSS2-RNAi tumor cells relative to control-RNAi tumor cells in 
LLC (A), B16 (B), Colon (C), and C127I cells (D) under normoxia.  
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Table 1  Effect of long-term (24 h) and short-term (2 h or 6 h) hypoxia in the [1-
14C]acetate 
uptake and ACSS2 gene expression 
  Ratio to each normoxic treatment 
Cell line Treatment [1-14C] acetate uptake Acss2 gene expression 
LLC Normoxia 1.00 ± 0.06a 1.00 ± 0.15a 
 Hypoxia with 2 h pretreatment 1.29 ± 0.14
b 1.42 ± 0.18b 
 Hypoxia with 6 h pretreatment 1.36 ± 0.07
b 1.63 ±  0.25b 
 Hypoxia with 24 h pretreatment 1.73 ± 0.29
b 1.81 ±  0.07b 
B16 Normoxia 1.00 ± 0.10a 1.00 ± 0.09a 
 Hypoxia with 2 h pretreatment 1.22 ± 0.07
b 1.46 ± 0.03b 
 Hypoxia with 6 h pretreatment 1.17 ± 0.05
b 1.14 ± 0.05c 
 Hypoxia with 24 h pretreatment 1.64 ± 0.08
c 1.98 ±  0.20d 
Colon Normoxia 1.00 ± 0.09a 1.00 ± 0.32a 
 Hypoxia with 2 h pretreatment 1.56 ± 0.18
b 1.59 ± 0.07b 
 Hypoxia with 6 h pretreatment 1.53 ± 0.07
b 1.71 ± 0.14b 
 Hypoxia with 24 h pretreatment 1.81 ± 0.04
c 3.28 ± 1.56b 
C127I Normoxia 1.00 ± 0.04a 1.00 ± 0.03a 
 Hypoxia with 2 h pretreatment 1.17 ± 0.06
b 1.12 ± 0.04b 
 Hypoxia with 6 h pretreatment 1.43 ± 0.18
b 1.62 ± 0.35b 
 Hypoxia with 6 h pretreatment 2.05 ± 0.11
c 2.58 ± 0.86b 
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3T3 Normoxia 1.00 ± 0.04 1.00 ± 0.05 
 Hypoxia with 2 h pretreatment 0.96 ± 0.07 0.59 ± 0.12 
 Hypoxia with 6 h pretreatment 0.91 ± 0.04 0.33 ± 0.08 
 Hypoxia with 24 h pretreatment 0.71 ± 0.05 1.09 ± 0.54 
a-d The significant differences are shown by different letters on each group （P < 0.05）. 
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Fig.1 
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Fig.2 
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Fig.3 
